Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Intergroup Rhabdomyosarcoma Study-II

H M Maurer1, E A Gehan, M Beltangady

  • 1Medical College of Virginia/Virginia Commonwealth University, Richmond 23298.

Cancer
|March 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Leukemia & lymphoma·2026
Same author

The effect of branded versus standardized e-cigarette packaging and device designs: an experimental study of youth interest in vaping products.

Public health·2024
Same author

Re: Some weighing of publication rates should be used to more fairly reflect the productivity of trainees. Re: re: Variation in UK Deanery publication rates in the British Journal of Oral and Maxillofacial Surgery: where are the current 'hot spots'?

The British journal of oral & maxillofacial surgery·2021
Same author

Variation in UK Deanery publication rates in the British Journal of Oral and Maxillofacial Surgery: where are the current 'hot spots'?

The British journal of oral & maxillofacial surgery·2020
Same author

Prevalence and pattern of energy drink intake among Australian adolescents.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2020
Same author

Setting up and maximising the usage of an Urgent Dental Care Centre in Blackpool. Sharing our experiences.

The British journal of oral & maxillofacial surgery·2020
Same journal

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

Cancer·2026
Same journal

Bendamustine in indolent lymphoma: Letting the dust settle down.

Cancer·2026
Same journal

Top advances of the year: Bispecific antibodies in early lines of therapy in multiple myeloma.

Cancer·2026
Same journal

Direct oral anticoagulants and warfarin in atrial fibrillation patients with cancer by anticoagulation quality.

Cancer·2026
Same journal

Sexual orientation and gender identity based disparities in colorectal, cervical, and breast cancer screening in the United States.

Cancer·2026
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
See all related articles

The Intergroup Rhabdomyosarcoma Study-II improved survival for children with rhabdomyosarcoma (RMS) by comparing treatment regimens. Overall survival saw an 8% increase compared to IRS-I, particularly in nonmetastatic cases.

Area of Science:

  • Pediatric Oncology
  • Clinical Trials
  • Rhabdomyosarcoma Research

Background:

  • The Intergroup Rhabdomyosarcoma Study (IRS)-II aimed to enhance survival and treatment for pediatric rhabdomyosarcoma (RMS).
  • This study built upon the findings and methodologies of the earlier IRS-I trial.

Purpose of the Study:

  • To evaluate and compare different therapeutic regimens for rhabdomyosarcoma in children.
  • To assess the impact of new treatment strategies on patient survival and disease-free survival rates.

Main Methods:

  • 999 previously untreated eligible patients were randomized into IRS Clinical Groups (I-IV) based on tumor site and histology.
  • Treatment outcomes were compared between various chemotherapy regimens (VAC, VA, VAdrC-VAC) and with historical data from IRS-I.

Related Experiment Videos

Main Results:

  • No significant differences in disease-free survival or survival were observed between VAC and VA in Group I (non-extremity alveolar RMS).
  • Intensive VA and repetitive-pulse VAC showed similar outcomes in Group II (non-extremity alveolar RMS).
  • Repetitive-pulse VAC and VAdrC-VAC demonstrated improved complete remission and survival rates in Group III compared to IRS-I, with CNS prophylaxis significantly boosting survival for cranial parameningeal sarcoma.

Conclusions:

  • The IRS-II trial demonstrated a significant overall 8% increase in 5-year survival rate for rhabdomyosarcoma patients compared to IRS-I.
  • The most substantial improvement in survival was observed in nonmetastatic patients, with rates increasing from 63% in IRS-I to 71% in IRS-II.